Evidence map›Paper›PMID 42251618›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Expanding

Olivier Perrin, Sarah Benkhoris, Johanne Vanney, Laurie Barthelemi, Vincent Boudousq, Emmanuel Deshayes, Claire Guisset, Ian Soulairol, Léa Rubira, Cyril Fersing and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Olivier PerrinPharmacy Department, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Sarah BenkhorisPharmacy Department, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Johanne VanneyPharmacy Department, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Laurie BarthelemiPharmacy Department, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Vincent BoudousqNuclear Medicine Department, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Emmanuel DeshayesNuclear Medicine Department, Institut régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
Claire GuissetPharmacy Department, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Ian SoulairolPharmacy Department, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Léa RubiraNuclear Medicine Department, Institut régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
Cyril FersingNuclear Medicine Department, Institut régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.
Daniele AlizéPharmacy Department, Nîmes University Hospital, University of Montpellier, Nîmes, France. daniele.alize@chu-nimes.fr.ORCID http://orcid.org/0009-0007-4350-8444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is a highly prevalent malignancy, and PET imaging targeting prostate-specific membrane antigen (PSMA) has become essential for assessing recurrence, metastatic spread and eligibility for radioligand therapy, with a 38% increase in PSMA PET activity reported in France between 2022 and 2023. [

resultsRadiolabeling was effective under all conditions that remained within the kit's buffer capacity. Single-generator labeling of complete vials or aliquots reliably yielded radiochemical purity (RCP) > 98% and stable complexes for 4 h. Aliquoting allowed for two separate preparations from a single Locametz

conclusionsAliquoting Locametz

Indexed as

Cold kitDouble elutionDual generatorsGallium-68PETProstate cancerPSMARadiolabeling optimizationRadiopharmaceuticalsRadiosynthesis

Identifiers

PMID42251618
PMCPMC13469061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.